Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma - PubMed (original) (raw)

Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma

R J Gilbertson et al. Br J Cancer. 1995 Mar.

Free PMC article

Abstract

The expression and prognostic significance of the c-erbB-2 oncogene product was studied in 55 cases of childhood medulloblastoma. Forty-six of the 55 tumours (83.6%) expressed the c-erbB-2 product. The percentage of tumour cells expressing the c-erbB-2 product proved to be a significant indicator of patient outcome when analysed as both a categorical and a continuous variable. As a categorical variable, patients with more than 50% positive tumour cells had a significantly worse survival, with only 10% alive at 10 years vs 48% for those with less than 50% positive tumour cells (log rank P = 0.0049). To demonstrate that this observed prognostic significance was both independent and not a result of 'data-driven' categorisation, it was also entered into the Cox model as a continuous variable. Prognostic significance was retained in P = 0.038.

PubMed Disclaimer

Similar articles

• Mitotic percentage index: a new prognostic factor for childhood medulloblastoma.
  Gilbertson RJ, Jaros E, Perry RH, Kelly PJ, Lunec J, Pearson AD. Gilbertson RJ, et al. Eur J Cancer. 1997 Apr;33(4):609-15. doi: 10.1016/s0959-8049(96)00516-3. Eur J Cancer. 1997. PMID: 9274443
• Potential prognostic value of C-erbB-2 expression in medulloblastomas in very young children.
  Herms JW, Behnke J, Bergmann M, Christen HJ, Kolb R, Wilkening M, Markakis E, Hanefeld F, Kretzschmar HA. Herms JW, et al. J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):510-5. doi: 10.1097/00043426-199711000-00004. J Pediatr Hematol Oncol. 1997. PMID: 9407936
• Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
  Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ. Gajjar A, et al. J Clin Oncol. 2004 Mar 15;22(6):984-93. doi: 10.1200/JCO.2004.06.032. Epub 2004 Feb 17. J Clin Oncol. 2004. PMID: 14970185
• Medullomyoblastoma: a radiographic and clinicopathologic analysis of six cases and review of the literature.
  Helton KJ, Fouladi M, Boop FA, Perry A, Dalton J, Kun L, Fuller C. Helton KJ, et al. Cancer. 2004 Sep 15;101(6):1445-54. doi: 10.1002/cncr.20450. Cancer. 2004. PMID: 15368333 Review.
• [Medulloblastoma in children. Prognostic incidence of vascular hyperplasia, coagulation necrosis and postoperative clinical state on survival].
  Maire JP, Guérin J, Rivel J, San Galli F, Bernard C, Dautheribes M, Caudry M. Maire JP, et al. Neurochirurgie. 1992;38(2):80-8. Neurochirurgie. 1992. PMID: 1603234 Review. French.

Cited by

• CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.
  Maher J, Davies DM. Maher J, et al. Biology (Basel). 2023 Feb 10;12(2):287. doi: 10.3390/biology12020287. Biology (Basel). 2023. PMID: 36829563 Free PMC article. Review.
• Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
  Vitanza NA, Johnson AJ, Wilson AL, Brown C, Yokoyama JK, Künkele A, Chang CA, Rawlings-Rhea S, Huang W, Seidel K, Albert CM, Pinto N, Gust J, Finn LS, Ojemann JG, Wright J, Orentas RJ, Baldwin M, Gardner RA, Jensen MC, Park JR. Vitanza NA, et al. Nat Med. 2021 Sep;27(9):1544-1552. doi: 10.1038/s41591-021-01404-8. Epub 2021 Jul 12. Nat Med. 2021. PMID: 34253928 Clinical Trial.
• Human epidermal growth factor receptor 2 expression in head and neck squamous cell carcinoma: Variation within and across primary tumor sites, and implications for antigen-specific immunotherapy.
  Warren EAK, Anil J, Castro PD, Kemnade J, Suzuki M, Hegde M, Hicks J, Yu W, Sandulache V, Sikora AG. Warren EAK, et al. Head Neck. 2021 Jul;43(7):1983-1994. doi: 10.1002/hed.26662. Epub 2021 Mar 4. Head Neck. 2021. PMID: 33660372 Free PMC article.
• Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
  Nellan A, Rota C, Majzner R, Lester-McCully CM, Griesinger AM, Mulcahy Levy JM, Foreman NK, Warren KE, Lee DW. Nellan A, et al. J Immunother Cancer. 2018 Apr 30;6(1):30. doi: 10.1186/s40425-018-0340-z. J Immunother Cancer. 2018. PMID: 29712574 Free PMC article.
• Exogenous HGF Bypasses the Effects of ErbB Inhibition on Tumor Cell Viability in Medulloblastoma Cell Lines.
  Zomerman WW, Plasschaert SL, Diks SH, Lourens HJ, Meeuwsen-de Boer T, Hoving EW, den Dunnen WF, de Bont ES. Zomerman WW, et al. PLoS One. 2015 Oct 23;10(10):e0141381. doi: 10.1371/journal.pone.0141381. eCollection 2015. PLoS One. 2015. PMID: 26496080 Free PMC article.

References

1. 1. Biometrics. 1973 Sep;29(3):579-84 - PubMed
2. 1. J Neurosurg. 1981 Jul;55(1):43-51 - PubMed
3. 1. J Histochem Cytochem. 1981 Apr;29(4):577-80 - PubMed
4. 1. J Neurosurg. 1982 Oct;57(4):446-51 - PubMed
5. 1. Cancer. 1983 Jan 15;51(2):312-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal